SGLT2 inhibitors for the treatment of pulmonary hypertension; new trends

Mohammad Memarian , Rahimeh Eskandarian *

Cited by CrossRef:

1- Karkoulias S, Leontsinis I, Iliakis P, Kallenou L, Tsiavos A, Soulaidopoulos S, Dri E, Manta E, Vlachakis P, Tsioufis P, Ktenopoulos N, Karakasis P, Dimitriadis K, Patsalis P, Chrysohoou C, Tsioufis K. Repurposing Heart Failure Therapies in Pulmonary Arterial Hypertension: Mechanistic Rationale, Translational Evidence, and Clinical Perspectives for SGLT2 Inhibitors and Mineralocorticoid Receptor Antagonists. Medicina. 2026;62(7):1345 [Crossref]

2- Cabré F, Cascante M. Present and Future Options for Pharmacotherapy in Cardiovascular Disease: Hemodynamic and Mechanistic Therapeutic Targets. Medical Sciences. 2026;14(2):331 [Crossref]